Good morning, ladies and gentlemen, and welcome to Rumble Incorporated fourth quarter and full year 2024 earnings call. (Operator Instructions) Please note, this event is being recorded. I will now ...

DelveInsight's "LUXTURNA Market Size, Forecast, and Market Insight Report" highlights the details around LUXTURNA, a one-time gene therapy for the treatment of patients with vision loss due to a ...

Since DeepSeek upstaged OpenAI in January with a powerful model that purportedly cost just several million dollars to build, China’s tech leaders have flooded the market with a rapid succession of low ...

LUXTURNA has significant market potential due to the high unmet need for effective treatments in rare genetic conditions. With its FDA approval for specific mutations in the RPE65 gene, it offers ...